LAUSR

MG7 antigen, a highly glycosylated CEACAM5 molecule, is specifically expressed in human gastrointestinal cancers. An MG7-CART therapy has been developed and showed great efficacy in gastric cancer PDX model. Here we present the first-in-human clinical trial results of MG7-CART therapy for metastasis colon cancer treatment. Distal metastasis was observed in pelvic cavity, peritoneal, spleen, liver and uterus after the patient received 6 rounds of bevacizumab plus EXLOX treatments. Intratumoral injections of MG7-CART (1-1.2x107/site) were given to the patient sequentially in peritoneal, spleen and uterus metastasis and two rounds of intravenous injections of MG7-CART (1x107 to 1.5x108) were given at the same time. Over 80% tumor necrosis could be observed in peritoneal and liver metastasis 40 days after injection and MG7-CART cell expansion could also be detected by PCR. During the treatment, the patient experienced transient body temperature increase and cytokine release. The first-in-human clinical trial result showed that MG7-CART therapy is efficacious and safe with no observed adverse effects. Citation Format: Jijun Yuan. The first-in-human clinical trial of MG7-CART for metastasis colon cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr CT056.